© 2022 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#COVID-19 treatment

Two scientists cooperating while examining antiviral drug in a test tube at laboratory
FDA Approves Remdesivir for Hospitalized COVID-19 Patients
coronavirus
NIH Study Aims To Identify Promising COVID-19 Treatments for Larger Trials
Senior patient in hospital bed nurse
How is COVID-19 treated?
Molnupiravir capsules (Merck)

FDA OKs Second COVID Antiviral Pill for Limited Use

Molnupiravir is authorized for people at high risk for severe COVID-19 when other treatment options are not available.
Paxlovid pills in production

FDA Authorizes First Antiviral Pill for COVID-19

Paxlovid, which reduces the risk of hospitalization or death by about 90%, is expected to be a game-changer.
Molnupiravir capsules (Merck)

FDA Advisors Recommend Antiviral Pill for Early COVID Treatment

Molnupiravir, the first oral antiviral for COVID-19, reduces the risk of hospitalization or death if started within five days.

Success of COVID Antiviral Pills Hinges on Access to Speedy and Accurate Tests

The new drugs must be used within a narrow window of time after developing symptoms.
Molnupiravir capsules (Merck)

Oral Antiviral Drug Cuts COVID-19 Hospitalization [UPDATED]

Molnupiravir reduces severe illness and death, but it must be started within days after developing symptoms.

Oral Antiviral Cuts COVID-19 Hospitalization by Nearly 90%

Paxlovid dramatically reduced the risk of severe illness and death, but it must be started soon after developing symptoms.
Istock

Long-Term Study of Children With COVID-19 Begins

NIH-supported research will track effects of coronavirus infection on children over three years.
Antibodies attacking SARS-CoV-2, the coronavirus that causes COVID-19

Is COVID-19 PrEP on the Horizon?

Post-exposure and pre-exposure prophylaxis could be a game-changer for immunocompromised people.

Scientists Search for Cause of Mysterious COVID-Related Inflammation in Children

MIS-C is a rare but life-threatening complication in which a hyperactive immune system attacks a child’s body.

Interferon Does Not Improve Outcomes for Hospitalized Adults with COVID-19

Treatment with interferon beta-1a plus the antiviral remdesivir was not superior to remdesivir alone.
National Institutes of Health director Francis Collins, MD, PhD

Francis Collins to Step Down as Director of the National Institutes of Health

Collins has led the NIH under three presidents over more than 12 years.

Will ‘Dr. Disinformation’ Ever Face the Music?

A steady stream of spurious claims about COVID-19 vaccines and treatments swirl around the public consciousness.

New Concerns About Coronavirus Evolution in Immunosuppressed Patients

Experts call for heightened precautions and better, more intensive therapies for COVID-19 patients with weakened immune systems.

Biden Administration Will Invest $3 Billion for COVID-19 Antiviral Development

The government-wide effort aims to develop the next generation of COVID-19 treatments to prepare the U.S. to respond to future virus threats

Airway-on-a-Chip Screens Drugs for Use Against COVID-19

Researchers used an airway-on-a-chip that mimics living lung tissue to screen approved drugs for use against SARS-CoV-2.

Oral Antiviral Drug Effective Against COVID-19 in Hamsters

Molnupiravir, previously studied for hepatitis C, might be able to prevent or treat COVID-19 outside of a clinical setting.
Advertisement
Ask COVID Health
Features